Abstract
Corticotropin-releasing factor (CRF) and cholecystokinin (CCK), two highly colocalized neuropeptides, have been linked to the etiology of stress-related anxiety disorders. Recent evidence points to the possibility that some of the anxiogenic effects of the central CCK system take place through interplay with the CRF system. The aim of the present study was to examine the effects of chronic, mild activation of CRF receptor 1 (CRF1) on the central CCK system of the C57BL/6J mouse. As shown by in situ hybridization, real-Time PCR and immunohistochemistry, 5 days of intracerebroventricular (i.c.v.) injections of a subeffective dose (2.3 pmol) of cortagine, a CRF1-selective agonist, resulted in an increase in CCK mRNA levels and CCK2 receptor immunoreactivity in several brain regions, such as amygdala and hippocampus, known to be involved in the regulation of anxiety. Mice with elevated endogenous central CCK tone exhibited significantly higher anxiety-like behaviors in the open-field task and elevated plus maze, and enhanced conditioned fear. These behavioral changes were reversed by i.c.v. administration of the CCK2-selective antagonist LY225910, after 5 days of priming with cortagine. Under the same conditions, the intraperitoneal administration of the CRF1 antagonist antalarmin was ineffective. This result indicated that once the CCK system was sensitized by prior CRF1 activation, it exhibited its anxiogenic effects, without influence by CRF1, possibly because of its observed downregulation. In sum, our results provide a novel model for the interaction of the CRF and CCK systems contributing to the development of hypersensitive emotional circuitry.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bradwejn J . Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci 1993; 18: 178–188.
Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM et al. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 2005; 57: 1485–1492.
Vanderhaeghen JJ, Signeau JC, Gepts W . New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 1975; 257: 604–605.
Rotzinger S, Vaccarino FJ . Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci 2003; 28: 171–181.
Dauge V, Lena I . CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 1998; 22: 815–825.
Bradwejn J, Koszycki D . Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 2001; 234: 19–27.
Harro J, Lofberg C, Rehfeld JF, Oreland L . Cholecystokinin peptides and receptors in the rat brain during stress. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 59–66.
Koks S, Vasar E, Soosaar A, Lang A, Volke V, Voikar V et al. Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol 1997; 7: 289–294.
Horinouchi Y, Akiyoshi J, Nagata A, Matsushita H, Tsutsumi T, Isogawa K et al. Reduced anxious behavior in mice lacking the CCK2 receptor gene. Eur Neuropsychopharmacol 2004; 14: 157–161.
Spiess J, Rivier J, Rivier C, Vale W . Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci USA 1981; 78: 6517–6521.
Vale W, Spiess J, Rivier C, Rivier J . Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981; 213: 1394–1397.
Chalmers DT, Lovenberg TW, De Souza EB . Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995; 15: 6340–6350.
Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000; 428: 191–212.
Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19: 162–166.
Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093–1102.
Bale TL, Contarino A, Smit GW, Chan R, Gold LH, Sawchenko PE et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24: 410–414.
Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24: 415–419.
Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A . Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 1999; 100: 207–215.
Rainnie DG, Bergeron R, Sajdyk TJ, Patil M, Gehlert DR, Shekhar A . Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci 2004; 24: 3471–3479.
Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K, Spiess J . Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci USA 2004; 101: 9468–9473.
Griebel G . Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 1999; 82: 1–61.
Gordon JA, Hen R . Genetic approaches to the study of anxiety. Annu Rev Neurosci 2004; 27: 193–222.
Bertoglio LJ, Zangrossi Jr H . Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Neurosci Biobehav Rev 2005; 29: 1361–1373.
Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP . In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996; 137: 5747–5750.
Franklin KBJ, Paxinos G . The Mouse Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA, 2001.
Radulovic J, Kammermeier J, Spiess J . Relationship between fos production and classical fear conditioning: effects of novelty, latent inhibition, and unconditioned stimulus preexposure. J Neurosci 1998; 18: 7452–7461.
Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)). Methods 2001; 25: 402–408.
Fanselow MS . Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 2000; 110: 73–81.
Noble F, Roques BP . CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 1999; 58: 349–379.
Barlow DH . Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997; 58: 32–36.
Meziane H, Devigne C, Tramu G, Soumireu-Mourat B . Distribution of cholecystokinin immunoreactivity in the BALB/c mouse forebrain: an immunocytochemical study. J chem Neuronat 1997; 12: 191–209.
Cain BM, Connolly K, Blum A, Vishnuvardhan D, Marchand JE, Beinfeld MC . Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J Comp Neurol 2003; 467: 307–325.
Bouton ME, Mineka S, Barlow DH . A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 2001; 108: 4–32.
Cohen H, Kaplan Z, Kotler M . CCK-antagonists in a rat exposed to acute stress: implication for anxiety associated with post-traumatic stress disorder. Depress Anxiety 1999; 10: 8–17.
Siegel RA, Duker EM, Pahnke U, Wuttke W . Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus. Neuroendocrinology 1987; 46: 75–81.
Nelovkov A, Areda T, Innos J, Koks S, Vasar E . Rats displaying distinct exploratory activity also have different expression patterns of gamma-aminobutyric acid- and cholecystokinin-related genes in brain regions. Brain Res 2006; 1100: 21–31.
Farook JM, Zhu YZ, Wang H, Moochhala S, Lee L, Wong PT . Strain differences in freezing behavior of PVG hooded and Sprague-Dawley rats: differential cortical expression of cholecystokinin2 receptors. Neuroreport 2001; 27: 17–20.
Chen Q, Nakajima A, Meacham C, Tang YP . Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc Natl Acad Sci USA 2006; 103: 3881–3886.
Davis M . Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry 1998; 44: 1239–1247.
LeDoux J . The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003; 23: 727–738.
Zarbin MA, Innis RB, Wamsley JK, Snyder SH, Kuhar MJ . Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 1983; 3: 877–906.
Moran TH, Schwartz GJ . Neurobiology of cholecystokinin. Crit Rev Neurobiol 1994; 9: 1–28.
Harro J, Pold M, Vasar E . Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 62–67.
Pikkarainen M, Ronkko S, Savander V, Insausti R, Pitkanen A . Projections from the lateral, basal, and accessory basal nuclei of the amygdala to the hippocampal formation in rat. J Comp Neurol 1999; 403: 229–260.
Petrovich GD, Canteras NS, Swanson LW . Combinatorial amygdalar inputs to hippocampal domains and hypothalamic behavior systems. Brain Res Brain Res Rev 2001; 38: 247–289.
Izquierdo I, Medina JH . Role of the amygdala, hippocampus and entorhinal cortex in memory consolidation and expression. Braz J Med Biol Res 1993; 26: 573–589.
Kim JJ, Rison RA, Fanselow MS . Effects of amygdala, hippocampus, and periaqueductal gray lesions on short- and long-term contextual fear. Behav Neurosci 1993; 107: 1093–1098.
Yaniv D, Vouimba RM, Diamond DM, Richter-Levin G . Simultaneous induction of long-term potentiation in the hippocampus and the amygdala by entorhinal cortex activation: mechanistic and temporal profiles. Neuroscience 2003; 120: 1125–1135.
Maren S, Quirk GJ . Neuronal signalling of fear memory. Nat Rev Neurosci 2004; 5: 844–852.
Tsutsumi T, Akiyoshi J, Isogawa K, Kohno Y, Hikichi T, Nagayama H . Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 1999; 33: 483–486.
Raud S, Innos J, Abramov U, Reimets A, Koks S, Soosaar A et al. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 2005; 181: 347–357.
Miyasaka K, Kobayashi S, Ohta M, Kanai S, Yoshida Y, Nagata A et al. Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci Lett 2002; 335: 115–118.
Swiergiel AH, Takahashi LK, Kalin NH . Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res 1993; 623: 229–234.
Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15: 5439–5447.
Sajdyk TJ, Gehlert DR . Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res 2000; 877: 226–234.
Mansi JA, Rivest S, Drolet G . Regulation of corticotropin-releasing factor type 1 (CRF1) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF. Endocrinology 1996; 137: 4619–4629.
Biro E, Sarnyai Z, Penke B, Szabo G, Telegdy G . Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 1993; 57: 340–345.
Kamilaris TC, Johnson EO, Calogero AE, Kalogeras KT, Bernardini R, Chrousos GP et al. Cholecystokinin-octapeptide stimulates hypothalamic-pituitary-adrenal function in rats: role of corticotropin-releasing hormone. Endocrinology 1992; 130: 1764–1774.
Peeters PJ, Gohlmann HW, Van den Wyngaert I, Swagemakers SM, Bijnens L, Kass SU et al. Transcriptional response to corticotropin-releasing factor in AtT-20 cells. Mol Pharmacol 2004; 66: 1083–1092.
Linthorst AC, Reul JM . Inflammation and brain function under basal conditions and during long-term elevation of brain corticotropin-releasing hormone levels. Adv Exp Med Biol 1999; 461: 129–152.
Matsuzaki I, Takamatsu Y, Moroji T . The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: behavioural and biochemical studies. Neuropeptides 1989; 13: 147–155.
Skelton KH, Nemeroff CB, Knight DL, Owens MJ . Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 2000; 20: 1240–1248.
Hokfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K . Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 1980; 12: 476–478.
van der Kooy D, Hunt SP, Steinbusch HW, Verhofstad AA . Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections. Neurosci Lett 1981; 26: 25–30.
Hendry SH, Jones EG, DeFelipe J, Schmechel D, Brandon C, Emson PC . Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci USA 1984; 81: 6526–6530.
Owens MJ, Nemeroff CB . Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43: 425–473.
Koob GF, Heinrichs SC . A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999; 848: 141–152.
Acknowledgements
We thank Dr Martin Rayner for helpful discussion during preparation of the manuscript. This work was supported by Max Planck Society, NIH grant 5U54NS039406-08 and NMRC grant (NMRC/0754/2003).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sherrin, T., Todorovic, C., Zeyda, T. et al. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Mol Psychiatry 14, 291–307 (2009). https://doi.org/10.1038/sj.mp.4002121
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4002121
Keywords
This article is cited by
-
Region-specific brain area reductions and increased cholecystokinin positive neurons in diabetic OLETF rats: implication for anxiety-like behavior
The Journal of Physiological Sciences (2020)
-
Cannabinoid CB1 receptors in the amygdalar cholecystokinin glutamatergic afferents to nucleus accumbens modulate depressive-like behavior
Nature Medicine (2019)
-
Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms
Translational Psychiatry (2011)